Canaccord Genuity Initiates Vertex Pharmaceuticals At Buy

Analysts at Canaccord Genuity initiated coverage on Vertex Pharmaceuticals Incorporated VRTX with a Buy rating. The target price for Vertex Pharmaceuticals is set to $150. Vertex Pharmaceuticals shares have jumped 99.24% over the past 52 weeks, while the S&P 500 index has gained 15.17% in the same period. Vertex Pharmaceuticals shares closed at $125.64 yesterday.